Chemomab Therapeutics Announces Annual General Meeting for July 2025

Chemomab Therapeutics ( (CMMB) ) just unveiled an announcement.

On May 27, 2025, Chemomab Therapeutics announced its upcoming Annual General Meeting of Shareholders, scheduled for July 1, 2025, in Ramat Gan, Israel. The meeting will cover key proposals, including the re-election of directors, approval of restricted share units for the CEO, and the re-appointment of the company’s independent accounting firm. Shareholders are encouraged to vote on these proposals, which are crucial for the company’s governance and strategic direction.

The most recent analyst rating on (CMMB) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Chemomab Therapeutics stock, see the CMMB Stock Forecast page.

Spark’s Take on CMMB Stock

According to Spark, TipRanks’ AI Analyst, CMMB is a Underperform.

Chemomab Therapeutics’ overall stock score is low due to significant financial challenges, including zero revenue and sustained losses. The technical analysis indicates mixed signals but does not currently show strong upward trends. The valuation metrics reflect high risk without profitability or income generation. The company’s future performance heavily relies on its ability to develop and commercialize products successfully.

To see Spark’s full report on CMMB stock, click here.

More about Chemomab Therapeutics

Chemomab Therapeutics Ltd. is a biotechnology company based in Tel Aviv, Israel, focusing on the development of therapies for fibrotic and inflammatory diseases. The company is involved in advanced clinical trials and aims to address unmet medical needs in these areas.

Average Trading Volume: 124,838

Technical Sentiment Signal: Sell

Current Market Cap: $25.74M

For an in-depth examination of CMMB stock, go to TipRanks’ Stock Analysis page.